Fig. 2: β-Glucan treatment promotes long-lasting disease tolerance against IAV infection.
From: β-Glucan reprograms neutrophils to promote disease tolerance against influenza A virus
a, Mice were infected with IAV with a lethal (survival and weight loss) or sublethal dose (viral load and pathology) at day 30 post-β-glucan treatment i.p. b,c, Weight loss (b) and survival (c) monitored over time (n = 10). d, Viral load quantified at days 3 and 6 post-infection (n = 4). e, Representative micrographs of lung histology from β-glucan (30 d)-treated mice stained with H&E at day 6 post-IAV infection. Scale bar, 200 μm. f, Lung histology at day 6 post-IAV infection after β-glucan long treatment (n = 5–6). Data are represented as mean ± s.e.m. Data were analyzed using two-tailed, unpaired Student’s t-test (f) or two-way ANOVA followed by Šidák’s multiple-comparison tests (d and e). Survival was monitored by a log(rank) test (c). *P < 0.05, ***P < 0.001, ****P < 0.0001. Illustrations in a created using BioRender.com.
